These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 7169836)

  • 21. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 22. Protection of human subjects; informed consent--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(17 pt 2):8942-58. PubMed ID: 10249528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paediatric clinical trials: redressing the imbalance.
    Schreiner MS
    Nat Rev Drug Discov; 2003 Dec; 2(12):949-61. PubMed ID: 14654794
    [No Abstract]   [Full Text] [Related]  

  • 24. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update of FDA's Critical Path Initiative.
    Khleif S
    Clin Adv Hematol Oncol; 2009 Mar; 7(3):173-4. PubMed ID: 19398939
    [No Abstract]   [Full Text] [Related]  

  • 26. Promoting public health and protecting consumers in a global economy: an overview of HHS/FDA's international activities.
    Kelly DP; Bachorik LL
    Food Drug Law J; 2005; 60(3):339-46. PubMed ID: 16304741
    [No Abstract]   [Full Text] [Related]  

  • 27. Regulatory perspectives on data monitoring.
    O'Neill RT
    Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Institute of Medicine's new drug safety report: implications for Canada.
    Cassels A
    CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086
    [No Abstract]   [Full Text] [Related]  

  • 29. FDA's conduct, review, and evaluation of inspections of clinical investigators.
    Turner G; Lisook AB; Delman DP
    Drug Inf J; 1987; 21(2):117-25. PubMed ID: 10282112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dying to live.
    Nat Med; 2006 Jun; 12(6):593. PubMed ID: 16760985
    [No Abstract]   [Full Text] [Related]  

  • 31. Pediatric drug trials. Challenge to FDA's authority may end up giving it more.
    Marshall E
    Science; 2002 May; 296(5569):820-1. PubMed ID: 11988539
    [No Abstract]   [Full Text] [Related]  

  • 32. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 33. PDA's response to FDA's "Guideline on sterile drug products produced by aseptic processing".
    Akers JE; Agalloco JP; Carleton FJ; Korczynski MS
    J Parenter Sci Technol; 1988; 42(4):114-7. PubMed ID: 3183865
    [No Abstract]   [Full Text] [Related]  

  • 34. The FDA's role in medical device clinical studies of human subjects.
    Saviola J
    J Neural Eng; 2005 Mar; 2(1):S1-4. PubMed ID: 15876645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical trials in Alzheimer disease. Comments on the project of FDA's guidelines].
    Spriet A; Dupin-Spriet T
    Therapie; 1993; 48(3):211-3. PubMed ID: 8140560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. When is a medical product too risky? An interview with FDA's top drug official. Interview by Tamar Nordenberg.
    Woodcock J
    FDA Consum; 1999; 33(5):8-11, 13. PubMed ID: 10522164
    [No Abstract]   [Full Text] [Related]  

  • 37. Prospects for reform of the IND/NDA processes: Part I.
    Romansky MA
    J Clin Psychopharmacol; 1982 Oct; 2(5):358-61. PubMed ID: 6752215
    [No Abstract]   [Full Text] [Related]  

  • 38. FDA's regulation of prescription drug labeling: a role for implied preemption.
    Kendrick LC
    Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
    [No Abstract]   [Full Text] [Related]  

  • 39. The FDA's enforcement of IRBs and patient informed consent.
    Kelsey FO
    Food Drug Cosmet Law J; 1989 Jan; 44(1):13-20. PubMed ID: 11651627
    [No Abstract]   [Full Text] [Related]  

  • 40. US looking for short cuts to speed drug approval.
    Ezzell C
    Nature; 1988 Aug; 334(6183):553. PubMed ID: 3043232
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.